THE ROLE OF PLASMA-LEVEL MONITORING IN CANCER-CHEMOTHERAPY

被引:1
作者
DONEHOWER, RC [1 ]
ERLICHMAN, C [1 ]
机构
[1] PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ONTARIO, CANADA
关键词
D O I
10.1016/0165-6147(81)90265-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:64 / 66
页数:3
相关论文
共 11 条
[1]  
ALBERTS DS, 1979, CLIN PHARMACOL THER, V26, P73
[2]  
BLEYER WA, 1978, CANCER-AM CANCER SOC, V41, P36, DOI 10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO
[3]  
2-I
[4]  
CHABNER BA, 1977, SEMIN ONCOL, V4, P165
[5]  
CROOKE ST, 1977, CANCER TREAT REP, V61, P1631
[6]  
FINN C, 1975, CANCER CHEMOTH REP 1, V59, P279
[7]  
MURINSON D, 1978, CLIN PHARMACOLOGY AN, P163
[8]  
PINEDO HM, 1976, CANCER RES, V36, P4418
[9]  
SPEYER JL, 1980, CANCER RES, V40, P567
[10]   USE OF PLASMA PHARMACOKINETICS TO PREDICT AND PREVENT METHOTREXATE TOXICITY [J].
STOLLER, RG ;
HANDE, KR ;
JACOBS, SA ;
ROSENBERG, SA ;
CHABNER, BA .
NEW ENGLAND JOURNAL OF MEDICINE, 1977, 297 (12) :630-634